Dimerix Limited announced the appointment of Associate Professor David Packham to the role of Chief Medical Officer (CMO) and provides an update on the development plan for its lead therapeutic program, DMX-200 for Chronic Kidney Disease (CKD). Through this new role, Associate Professor Packham will drive the continuing DMX-200 clinical programs. He will be responsible for the identification and engagement of clinical trial sites in Australia and will help to define and identify patient populations, particularly with respect to the rare disease Focal segmental glomerulosclerosis, a rare disease which causes nephrotic syndrome in children and adolescents and is a leading cause of kidney failure in adults. He will also be tasked with leading communications with international key opinion leaders.